JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anderson, M. E.
Right arrow Articles by Roden, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anderson, M. E.
Right arrow Articles by Roden, D. M.

Vol. 296, Issue 3, 806-810, March 2001

Potassium Current Antagonist Properties and Proarrhythmic Consequences of Quinolone Antibiotics

Mark E. Anderson, Alexander Mazur, Tao Yang and Dan M. Roden

Vanderbilt University Medical Center, Departments of Internal Medicine and Pharmacology, Divisions of Clinical Pharmacology and Cardiovascular Medicine, Nashville, Tennessee (M.E.A., T.Y., D.M.R.); and Department of Cardiology, Rabin Medical Center, Belinson Campus and Sackler School of Medicine, Tel Aviv University, Israel (A.M.)

Quinolones are clinically important antibiotic drugs. One quinolone antibiotic, sparfloxacin (SPX), has been recently reported to increase the QT interval, and another quinolone, grepafloxacin (GRX), was withdrawn because it induced torsade de pointes (TdP), a polymorphic ventricular tachycardia (VT) linked to excessive QT interval prolongation. To determine whether SPX, GRX, and other recently developed quinolones, gatifloxacin (GAT) and moxifloxacin (MOX), have similar, potentially deleterious, properties we compared these agents in two ways. First, we measured their relative antagonist potency against the rapid component of the delayed rectifier K+ current (IKr), and second we determined the QT interval prolongation and inducibility of VT and TdP using a well established in vivo rabbit arrhythmia model. All of these agents are IKr antagonists with the following IC50 values (mean ± S.E.) for IKr block: SPX, 0.23 ± 0.07 µM; MOX, 0.75 ± 0.31 µM; GAT, 26.5 ± 13.4 µM; and GRX, 27.2 ± 11.6 µM. All agents also increased the maximum QT interval (mean ± S.E.) from baseline (241 ± 10 ms): SPX, 370 ± 30 ms; MOX, 270 ± 30 ms; GRX, 280 ± 25 ms; and GAT, 255 ± 23 ms. No agents caused TdP during a standard 30-min observation period, but SPX-treated animals developed nonsustained VT (three of six) and TdP (one of six) during an extended 60-min observation period. These findings show that IKr block may be a common feature of many quinolone antibiotics, and that the proarrhythmic consequences vary according to IKr antagonist potency, but are also influenced by additional, unidentified factors.


0022-3565/01/2963-0806$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
T. Wisialowski, K. Crimin, J. Engtrakul, J. O'Donnell, B. Fermini, and A. A. Fossa
Differentiation of Arrhythmia Risk of the Antibacterials Moxifloxacin, Erythromycin, and Telithromycin Based on Analysis of Monophasic Action Potential Duration Alternans and Cardiac Instability
J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 352 - 359.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Y. A. Kuryshev, E. Ficker, L. Wang, P. Hawryluk, A. T. Dennis, B. A. Wible, A. M. Brown, J. Kang, X.-L. Chen, K. Sawamura, et al.
Pentamidine-Induced Long QT Syndrome and Block of hERG Trafficking
J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 316 - 323.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
K. M. Smith and B. M. Lomaestro
What Role do Fluoroquinolone Antimicrobial Agents Play in Cardiac Dysfunction and Altered Glycemic Control?
Journal of Pharmacy Practice, October 1, 2003; 16(5): 349 - 360.
[Abstract] [PDF]


Home page
JAMAHome page
S. M. Al-Khatib, N. M. A. LaPointe, J. M. Kramer, and R. M. Califf
What Clinicians Should Know About the QT Interval
JAMA, April 23, 2003; 289(16): 2120 - 2127.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.